SEC Comment Letter for PALISADE BIO, INC. (PALI) (CIK 0001357459) (PALI) — Feb 11, 2009
PALISADE BIO, INC. (PALI) (CIK 0001357459)
Date: Feb. 11, 2009 · CIK: 0001357459 · Accession: 0000000000-09-007255
AI Filing Summary & Sentiment
File numbers found in text: 333-157079
Show Raw Text
Mail Stop 6010 February 11, 2009 I. Richard Garr Chief Executive Officer Neuralstem, Inc. 9700 Great Seneca Highway Rockville, Maryland 20850 Re: Neuralstem, Inc. Registration Statement on Form S-3 Filed February 2, 2009 File No. 333-157079 Dear Mr. Garr: We have limited our review of your filing to those issues we have addressed in our comments. Where indicated, we think you should revise your document in response to these comments. If you disagree, we w ill consider your explanation as to why our comment is inapplicable or a revision is unneces sary. Please be as detailed as necessary in your explanation. In some of our comme nts, we may ask you to provide us with information so we may better understand your disclosure. After reviewing this information, we may raise additional comments. Please understand that the purpose of our re view process is to assist you in your compliance with the applicable disclosure requirements and to enhance the overall disclosure in your filing. We look forward to working with you in these respects. We welcome any questions you may have about our comments or any other aspect of our review. Feel free to call us at the telephone numbers listed at the end of this letter. General 1. We note your disclosure in footnote 1 to th e registration fee table that pursuant to Rule 416, the registration statement also covers additional co mmon shares that may be offered to prevent dilution as a re sult of stock splits, stock dividends or that may be required for delivery upon exer cise of any warrants as a result of anti- dilution provisions. Rule 416(a) involves the registration of additional securities “being offered or issued to prevent di lution resulting from stock splits, stock dividends or similar transactions.” Pleas e revise to remove the shares “that may be required for delivery upon exercise of any warrants as a result of anti-dilution provisions” as they do not appear to be covered by Rule 416. I. Richard Garr Neuralstem, Inc. February 11, 2009 Page 2 Incorporation of Certain Info rmation by Reference, page 17 2. Please revise this section to incorpor ate by reference the Form 8-Ks filed on November 18, 2008, December 3, 2008, December 18, 2008 and January 29, 2009. Exhibits, page 20 3. Please file a copy of your Se ries C Warrant as an exhi bit to this registration statement. * * * As appropriate, please amend your regist ration statement in response to these comments. You may wish to provide us with marked copies of the amendment to expedite our review. Please furnish a cove r letter with your amendment that keys your responses to our comments and provides any requested information. Detailed cover letters greatly facilitate our review. Please understand that we may have additional comments after reviewing your amendmen t and responses to our comments. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes all in formation required under the Securities Act of 1933 and that they have provided all information investors require for an informed investment decision. Since the company and its management are in possession of all facts relating to a company’ s disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made. Notwithstanding our comments, in the ev ent the company requests acceleration of the effective date of the pending registration statement, it should furnish a letter, at the time of such request, acknowledging that: • should the Commission or the staff, acting purs uant to delegated authority, declare the filing effective, it does not foreclose th e Commission from taking any action with respect to the filing; • the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and • the company may not assert staff comments a nd the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. I. Richard Garr Neuralstem, Inc. February 11, 2009 Page 3 In addition, please be advi sed that the Division of En forcement has access to all information you provide to the staff of the Di vision of Corporation Finance in connection with our review of your filing or in response to our comments on your filing. We will consider a written request for acceleration of the effective date of the registration statement as conf irmation of the fact that t hose requesting acceleration are aware of their respective re sponsibilities under the S ecurities Act of 1933 and the Securities Exchange Act of 1934 as they rela te to the proposed public offering of the securities specified in the above registration statement. We will act on the request and, pursuant to delegated authority, grant acce leration of the effective date. We direct your attention to Rules 460 and 461 regarding requesting acceleration of a registration statement. Please allow ad equate time after the filing of any amendment for further review before submitting a request for acceleration. Please provide this request at least two business days in a dvance of the requested effective date. Please contact Jennifer Riegel at ( 202) 551-3575 or me at (202) 551-3715 with any questions. S i n c e r e l y , J e f f r e y P . R i e d l e r A s s i s t a n t D i r e c t o r cc: Raul Silvestre Law Offices of Raul Silvestre & Associates, APLC 31200 Via Colinas, Suite 200 Westlake Village, CA 91362